Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04822064
Other study ID # IN DEXKET rescue
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 22, 2022
Est. completion date December 31, 2025

Study information

Verified date November 2023
Source Seoul National University Hospital
Contact Jin-Tae Kim, MD. PhD
Phone 82-2-2072-3664
Email jintae73@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In Korea, oral chloral hydrate is still widely used for pediatric procedural sedation. The primary objective of the study is to evaluate the effect of intranasal dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) on the success rate of rescue sedation after failed sedation (PSSS=4,5) with chloral hydrate (50mg/kg) The hypothesis of this study is that the intranasal dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) will improve the success rate of rescue sedation (PSSS=1,2,3) within 15 minutes. This is a prospective, parallel-arm, single-blinded, multi-center, randomized controlled trial comparing the effect of intranasal dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) with oral chloral hydrate (50mg/kg) in pediatric patients after failed sedation attempt with oral chloral hydrate. Prior to the procedure, each patient will be randomized in the control arm (oral chloral hydrate) or study arm (intranasal dexmedetomidine and ketamine).


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 7 Years
Eligibility Inclusion Criteria: - Pediatric patients who need procedural sedation (Age < 7 years) - ASA (American Society of Anesthesiologists) physical status 1-3 - Failed to induce sedation with oral chloral hydrate 50mg/kg Exclusion Criteria: - ASA (American Society of Anesthesiologists) physical status 4-5 - History of hypersensitivity to Dexmedetomidine, Ketamine, or Chloral hydrate - Recent administration of Alpha 2 adrenergic receptor agonist or antagonist - Cannot administrate oral medication (e.g. Swallowing difficulty) - Cannot administrate intranasal medication(e.g. Excessive rhinorrhea) - Unstable vital signs, Unstable arrhythmia

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Intranasal dexmedetomidine and ketamine
Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
Oral chloral hydrate
Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)

Locations

Country Name City State
Korea, Republic of Jin-Tae Kim Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (8)

Abdel-Ghaffar HS, Kamal SM, El Sherif FA, Mohamed SA. Comparison of nebulised dexmedetomidine, ketamine, or midazolam for premedication in preschool children undergoing bone marrow biopsy. Br J Anaesth. 2018 Aug;121(2):445-452. doi: 10.1016/j.bja.2018.03.039. Epub 2018 Jun 22. — View Citation

Cao Q, Lin Y, Xie Z, Shen W, Chen Y, Gan X, Liu Y. Comparison of sedation by intranasal dexmedetomidine and oral chloral hydrate for pediatric ophthalmic examination. Paediatr Anaesth. 2017 Jun;27(6):629-636. doi: 10.1111/pan.13148. Epub 2017 Apr 17. — View Citation

Jun JH, Kim KN, Kim JY, Song SM. The effects of intranasal dexmedetomidine premedication in children: a systematic review and meta-analysis. Can J Anaesth. 2017 Sep;64(9):947-961. doi: 10.1007/s12630-017-0917-x. Epub 2017 Jun 21. — View Citation

Poonai N, Canton K, Ali S, Hendrikx S, Shah A, Miller M, Joubert G, Rieder M, Hartling L. Intranasal ketamine for procedural sedation and analgesia in children: A systematic review. PLoS One. 2017 Mar 20;12(3):e0173253. doi: 10.1371/journal.pone.0173253. eCollection 2017. — View Citation

Sheta SA, Al-Sarheed MA, Abdelhalim AA. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: a double-blinded randomized controlled trial. Paediatr Anaesth. 2014 Feb;24(2):181-9. doi: 10.1111/pan.12287. Epub 2013 Nov 15. — View Citation

Zanaty OM, El Metainy SA. A comparative evaluation of nebulized dexmedetomidine, nebulized ketamine, and their combination as premedication for outpatient pediatric dental surgery. Anesth Analg. 2015 Jul;121(1):167-171. doi: 10.1213/ANE.0000000000000728. — View Citation

Zhang W, Fan Y, Zhao T, Chen J, Zhang G, Song X. Median Effective Dose of Intranasal Dexmedetomidine for Rescue Sedation in Pediatric Patients Undergoing Magnetic Resonance Imaging. Anesthesiology. 2016 Dec;125(6):1130-1135. doi: 10.1097/ALN.0000000000001353. — View Citation

Zhang W, Wang Z, Song X, Fan Y, Tian H, Li B. Comparison of rescue techniques for failed chloral hydrate sedation for magnetic resonance imaging scans--additional chloral hydrate vs intranasal dexmedetomidine. Paediatr Anaesth. 2016 Mar;26(3):273-9. doi: 10.1111/pan.12824. Epub 2015 Dec 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Success rate of adequate rescue sedation (PSSS = 1, 2, 3) within 15 minutes % Success rate of adequate rescue sedation (Pediatric Sedation State Scale= 1,2,3) within 15 minutes after sedative administration. % During pediatric procedural sedation (up to 1 hour)
Secondary Onset time of rescue sedation (PSSS =1,2,3) (min) Onset time of rescue sedation (Pediatric Sedation State Scale= 1,2,3) after rescue sedative administration. During pediatric procedural sedation (up to 3 hour)
Secondary Duration of rescue sedation = Recovery time (PSSS =4,5) Pediatric Sedation State Scale= 4,5 after recovery of sedation During pediatric procedural sedation (up to 3 hour)
Secondary PSSS(Pediatric Sedation State Scale, 0-5) 5 Patient is moving in a manner that impedes the proceduralist and requires forceful immobilization.
4 Moving during the procedure that requires gentle immobilization for positioning.
3 Expression of pain or anxiety on face, but not moving or impeding completion of the procedure.
2 Quiet (asleep or awake), not moving during procedure, and no frown (or brow furrow) indicating pain or anxiety.
1 Deeply asleep with normal vital signs, but requiring airway intervention and/or assistance 0 Sedation associated with abnormal physiologic parameters that require acute intervention q 10min
During pediatric procedural sedation (up to 3 hour)
Secondary HR during sedation (/min) HR(/min) at Baseline(T0), q 10min During pediatric procedural sedation (up to 3 hour)
Secondary SpO2 during sedation (%) SpO2(%) by pulse oximetry at Baseline(T0), q 10min During pediatric procedural sedation (up to 3 hour)
Secondary Respiratory rate during sedation (/min) RR(/min) at Baseline(T0), q 10min During pediatric procedural sedation (up to 3 hour)
Secondary the incidence of PSSS=0 (Abnormal physiologic parameter that require acute intervention) % the incidence of PSSS=0 (Abnormal physiologic parameter that require acute intervention) % During pediatric procedural sedation (up to 3 hour)
Secondary The incidence of respiratory intervention: Manual ventilation or Artificial airway % The incidence of respiratory intervention: Manual ventilation or Artificial airway % During pediatric procedural sedation (up to 3 hour)
Secondary The incidence of significant desaturation (SpO2 < 95% or -10% from baseline, >10 seconds) % The incidence of significant desaturation (SpO2 < 95% or -10% from baseline, >10 seconds) % During pediatric procedural sedation (up to 3 hour)
Secondary The incidence of significant apnea (>20seconds) % The incidence of significant apnea (>20seconds) % During pediatric procedural sedation (up to 3 hour)
Secondary The lowest SpO2 value (%) The lowest SpO2 value (%) During pediatric procedural sedation (up to 3 hour)
Secondary The incidence of hemodynamic intervention: fluid management, intravenous medication % The incidence of hemodynamic intervention: fluid management, intravenous medication % During pediatric procedural sedation (up to 3 hour)
Secondary The incidence of significant bradycardia (-30% from baseline) % The incidence of significant bradycardia (-30% from baseline) % During pediatric procedural sedation (up to 3 hour)
Secondary The incidence of significant hypotension (-30% from baseline) % The incidence of significant hypotension (-30% from baseline) % During pediatric procedural sedation (up to 3 hour)
Secondary Patients' acceptance (1=excellent, 2=good, 3=fair, 4=poor) Patients' acceptance (1=excellent, 2=good, 3=fair, 4=poor) During pediatric procedural sedation (up to 3 hour)
Secondary Separation anxiety (1=easy, 2=whimper, 3=cry, 4=cry and cling to parents) Separation anxiety (1=easy, 2=whimper, 3=cry, 4=cry and cling to parents) During pediatric procedural sedation (up to 3 hour)
Secondary Physicians' satisfaction (1=excellent, 2=good, 3=fair, 4=poor) Physicians' satisfaction (1=excellent, 2=good, 3=fair, 4=poor) During pediatric procedural sedation (up to 3 hour)
Secondary The incidence of Other side effects (Ex: Nausea/Vomit, Allergic reaction, Etc) The incidence of Other side effects (Ex: Nausea/Vomit, Allergic reaction, Etc) During pediatric procedural sedation (up to 3 hour)
Secondary The incidence of Rescue sedation failure (PSSS =0,4,5) after 30 min % The incidence of Rescue sedation failure (PSSS =0,4,5) after 30 min % During pediatric procedural sedation (up to 3 hour)
Secondary The incidence of Completion of procedure The incidence of Completion of procedure During pediatric procedural sedation (up to 3 hour)
Secondary Total cost of sedation (KRW) Total cost of sedation (KRW) During pediatric procedural sedation (up to 1 day)
See also
  Status Clinical Trial Phase
Recruiting NCT03399019 - Bispectral Index(BIS) on Depth of Sedation With Dexmedetomidine, Propofol and Midazolam During Spinal Anesthesia N/A
Completed NCT03220880 - Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures
Recruiting NCT04820205 - Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Procedural Sedation in Children N/A
Recruiting NCT04549623 - End-Tidal Carbon Dioxide Monitoring Device for Sedation During Endoscopic Ultrasonography N/A
Completed NCT01527903 - A Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation in the Intensive Care Unit Phase 4
Completed NCT01001533 - Assess the Ability of Electrical Cardiometry to Trend Hemodynamic Variables During Dexmedetomidine Sedation N/A
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1
Completed NCT00158873 - Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects Phase 4
Terminated NCT00205517 - Sedation and Psychopharmacology in Critical Care N/A
Recruiting NCT04096768 - The Use of Ketamine and Dexmedetomidine in Intensive Care Sedation Phase 3
Active, not recruiting NCT05082623 - The Effect of Music on Delirium, Pain, Need of Sedation, Anxiety and Vital Parameters N/A
Suspended NCT03285165 - Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients Phase 2/Phase 3
Active, not recruiting NCT04788589 - Sedation and Ventilator Weaning Protocol in PICU N/A
Completed NCT03425474 - Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy Phase 3
Recruiting NCT06061159 - The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction Phase 4
Completed NCT06449365 - Comparison of Intravenous V/S Nasal Atomizer Delivery of Midazolam for Conscious Sedation for No-scalpel Vasectomy Phase 4
Completed NCT02171910 - Doxapram as an Additive to Propofol Sedation in Sedation for ERCP Phase 4
Completed NCT02211118 - Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD Phase 4
Completed NCT01694745 - EUROpean Pain Audit In Neonates N/A
Completed NCT00997126 - Propofol Versus Alfentanil Versus Nitrous Oxide for Moderate Procedural Sedation Phase 4